IDEXX Laboratories, Inc. (IDXX) - Stock Analysis
Last updated: Mar 8, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Selected as a solid growth name with raised 2025 guidance supported by strong diagnostic product adoption and margin expansion; upcoming Nov 3 Q3 earnings represent key catalyst amid moderate technical weakness requiring caution.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠High margins ⢠Strong cash flow ⢠Elevated multiples IDEXX combines very high profitability and cash generation with manageable leverage but faces modest liquidity and stretched valuation that limit downside protection.
Price Behavior
Key Price Behavior Insights: ⢠Short-term weakness ⢠Oversold band ⢠Resistance cluster Support Level: $623.13 Resistance Level: $656â$661 Price sits at a last-month lowâ$608.41 is ~4.6% below the last-month SMA (~$637.80), having broken the $623.13 support and now facing resistance at $656â$661, signaling short-term weakness with only a reclaim of the SMA likely to pause the selloff.
Sentiment & News
Key News Insights: ⢠Recurringârevenue momentum ⢠Mixed fund flows ⢠Insider selling & risk IDEXX is highlighted for strong diagnostic, point-of-care and cloud recurringârevenue momentum and active investor outreach, but mixed institutional buying/selling, insider sales and a solvency flag introduce meaningful downside risk.
AI Summary
IDEXX's premium valuation now depends less on pure growth and more on demonstrable durability in petâvisit volumes and flawless execution of pointâofâcare rollouts/international expansionâwait for consistent EPS/guidance beats, margin improvement from software/assay mix, or disciplined buybacks at lower multiples before assuming current multiples are justified, because small misses can create outsized downside.
Description
IDEXX Laboratories develops, manufactures, and sells diagnostic instruments, consumables, laboratory services, and practice management software for veterinary, livestock, dairy and water-testing markets worldwide. Its offerings include point-of-care and reference laboratory diagnostics, imaging and monitoring systems, and microbiological water tests, supported by sales, technical service teams and distribution partners. The company also supplies certain human point-of-care analyzers; it was founded in 1983 and is headquartered in Westbrook, Maine.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Nov 3 | Nov 10 | IDXX | IDEXX Laboratories, Inc. | Selected as a solid growth name with raised 2025 guidance supported by strong diagnostic product adoption and margin expansion; upcoming Nov 3 Q3 earnings represent key catalyst amid moderate technical weakness requiring caution. | Closed | -1.8% |